Events
Bio-Europe Spring 2026
Lisbon, Portugal
23rd March 2026
Meet Axoltis Pharma at BIO-Europe Spring in Lisbon !
Yann GODFRIN, Ph.D., CEO, Nicolas REBERGUE, PhD, Project Manager will be glad to meet for partnerging discussion.
Axoltis Pharma is a phase 2 clinical stage biotech company with a head start thanks to NX210c, our product for restoring blood brain barrier integrity in neurodegenerative diseases.
SEALS is a phase 2 clinical trial evaluating efficacy of NX210c in ALS patients. The last patient has been enrolled and the topline results are expected from Q2 2026.
